Ser37
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser37  -  GATA6 (human)

Site Information
REPStPPsPIsSSSS   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 15419868

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 2 ) , mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 ) , mutation of modification site ( 2 ) , phospho-antibody ( 2 ) , western blotting ( 2 )
Disease tissue studied:
luminal A breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 ) , colorectal cancer ( 2 ) , colorectal carcinoma ( 2 ) , lung cancer ( 4 ) , non-small cell lung cancer ( 4 ) , pancreatic ductal adenocarcinoma ( 3 )
Relevant cell line - cell type - tissue:
'pancreatic, ductal'-pancreas ( 3 ) , 293 (epithelial) ( 5 , 6 , 7 , 8 , 9 ) , breast ( 1 ) , DLD1 (intestinal) ( 2 ) , HCC366 (pulmonary) ( 4 ) , HCC78 (pulmonary) ( 4 ) , HCT8 (intestinal) ( 2 ) , HOP62 (pulmonary) ( 4 ) , HT-29 (intestinal) ( 2 ) , NCI-H322 (pulmonary) ( 4 )

Upstream Regulation
Putative in vivo kinases:
GSK3B (human) ( 2 )
Treatments:
CT-99021 ( 2 ) , serum_starvation ( 2 ) , TNF ( 2 )

Downstream Regulation
Effects of modification on GATA6:
protein degradation ( 2 )
Effects of modification on biological processes:
transcription, induced ( 2 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Chitforoushzadeh Z, et al. (2016) TNF-insulin crosstalk at the transcription factor GATA6 is revealed by a model that links signaling and transcriptomic data tensors. Sci Signal 9, ra59
27273097   Curated Info

3

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

4

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

5

Guo A (2010) CST Curation Set: 9972; Year: 2010; Biosample/Treatment: cell line, 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368
Curated Info

6

Guo A (2010) CST Curation Set: 9975; Year: 2010; Biosample/Treatment: cell line, 293/mTOR inhibitor; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368
Curated Info

7

Guo A (2010) CST Curation Set: 9973; Year: 2010; Biosample/Treatment: cell line, 293/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368
Curated Info

8

Guo A (2010) CST Curation Set: 9971; Year: 2010; Biosample/Treatment: cell line, 293/mTOR inhibitor; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368
Curated Info

9

Guo A (2010) CST Curation Set: 9974; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368
Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.